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ABSTRACT
A proof-of-concept microfluidic device combined with heparin-immobilized magnetic beads was
created to concentrate cytokine proteins collected from microdialysis samples. Cytokines are known to be
related to several diseases such as cancer, and Parkinson’s diseases, so to be able to develop more
effective diseases treatments their interactions have to be well understood. Amine-functionalized
polystyrene and carboxyl-functionalized magnetic microspheres of ~6.0 µm in diameter were used to
-8

-

immobilize heparin. The amount of heparin immobilized on polystyrene beads was 5.82 x 10 ± 0.36 x 10
8

6

-8

-8

6

M per 1.0 x 10 beads and for magnetic beads was 0.64 x 10 ± 0.01 x 10 M per 1.0 x 10 beads. The

minimum initial heparin concentration needed to bind ~ 100% cytokines was 36.8 µM based on
estimations for a fixed initial concentration (1.0 nM) of cytokines. For polystyrene beads, it was found that
0.1 and 1.0 nM ratCCL2 (MCP-1) bound to immobilized heparin at levels of 94.50 and 83.67%,
respectively. For heparin immobilized magnetic beads, experimental percentages of cytokine bound to
heparin were 70.38 ± 1.71 % (ratCCL2, 0.57 nM) and 11.07 % (ratTNF-α, 0.09 nM). The differences
between experimental and estimated percentages of cytokine bound to heparin were 28.31 and 31.56%
for ratCCL2 and ratTNF-α. A microfluidic system was designed and made of polydimethylsiloxane
(PDMS) with soft lithography. The dimensions were as follows: a) Inlet channel width of 0.1 mm, b)
circular trapping area of 3.6 mm in diameter, and c) outlet channel width of 0.2 mm. The equivalent circuit
theory was used to estimate the pressure drop for each channel at a flow rate of 1.0 µL/min. Estimated
Reynolds numbers for each channel were low (0.17, 0.01, and 0.11) in agreement with the theory.
Estimated pressure drops were 112.2, 0.20, and 30.28 Pa. Using different flow rates, the infusion of
magnetic microspheres into the device and their “spreading” behavior within circular channel was
observed and quantified. “Spreading” behavior of magnetic microspheres on a circular channel could be
controlled by changing their flow rate. Controlling the behavior of magnetic microspheres is very crucial
for pre-concentration of cytokine proteins on bead-based microfluidic devices. This microfluidic device is
now ready for testing of the trapping and preconcentration of cytokines in real microdialysis samples.
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CHAPTER 1. INTRODUCTION: Background and Significance

1.1 Cytokine
1.1.1

Overview and importance in biomedicine
Cytokines are vitally important signaling proteins generated during an immunological response.

Whicher and Evans stated that “cytokines are peptides used by immune and inflammatory cells to
1

communicate with each other and control the milleu interieur in which they operate”. Their molecular
11

weight ranges between 8 to 80 kDa.

Cytokines or “chemical messengers” are released “by white blood
12,13

cells and several other cell types in the body”.
13

immune response.

Several families of cytokines are released during an
2

1,3

These proteins are often dysregulated in diseases such as diabetes, cancer,
4

13

Parkinson’s disease. These cytokines act coordinately as a network.

and

As a result, a multiplexed analysis

rather than one cytokine at a time analysis is necessary for determining the level of the network. There is
an enormous interest in monitoring the concentration changes of cytokines in living systems during some
disease stages.
Typically, cytokines are collected from blood and tissue samples. The problem with sampling
cytokines from blood and tissue is that obtaining in situ and in real-time concentration changes of
cytokines directly within the tissue is not possible. In contrast, microdialysis sampling methods can be
used along with other techniques to measure and monitor cytokines concentration changes in situ and in
real-time, see section 1.2. Cytokines are normally present in low concentrations (picomolar or femtomolar
6,7,8

range).

According to Ao and Stenken most cytokines have a high biological activity and
5

concentration changes within living systems.

rapid

Therefore, quantitation of cytokine proteins is very

challenging and requires highly sensitive detection methods such as antibody-based enzyme linked
immunoassay (ELISA).
1.1.2

Cytokines detection methods or assays
Several research groups have worked on the development of detection methods to improve the

quantitation of cytokines in living systems. Whiteside wrote a helpful review article about cytokines
10

assays.

In this article she pointed out that immunoassays for cytokines such as ELISA are commonly
1

used because of “their acceptable specificity, sensitivity, rapid turnaround time, convenience, ease of
10

performance, and a relatively low cost”.

Also, she classified the available methods for cytokines
10

assessment in body fluids, cells, and tissues.

She mentioned that immunocytochemistry,

immunofluorescence, and mRNA-based assays are the methods available for the detection of cytokines
10

in tissues.

On the other hand,

according to Remick, et al., the basic ELISA protocol takes
9

approximately 19 hours to get the results. This is one of the main issues of using ELISA to quantify
biomolecules or cytokines along with the sample size requirement of at least 100 µL and the labor
intensity or tediousness of the process.
Pre-concentration of biomolecules or proteins is widely used by many research groups and
14-19

industrial processes.

As mentioned above, proteins such as cytokines can be present in picomolar to

femtomolar concentrations. The problem is that commonly used analytical instruments or methods for
protein quantitation such as ELISA can only measure down to 31.25 pg/mL or 2.39 pM (MCP-1, for
20

example) (BD bioscience ELISA’s kit) without making any changes to the standard protocol.

Also,

commonly used analytical methods for protein quantitation require mimumum volumes of at least 50 µL or
20

100 µL.

That is why it is very important to develop a method or system coupled to a sampling technique

to be able to pre-concentrate cytokines and measure them using smaller sample volumes (1 µL) than the
ELISA methods. In addition, the fact that some cytokines are present in low pg/mL concentrations and
sampling techniques such as microdialysis has low extraction efficiencies when sampling cytokines
represents a challenge for the development of the sampling system.
Monitoring concentration changes of cytokines over time is crucial to study the immune-related
interactions of cytokines within living systems during disease states. Therefore, it is necessary to use
minimally invasive sampling methods such as microdialysis in order to track the concentration changes
over time. Finally, it is very important to understand the diffusive limitations of microdialysis sampling in
order to overcome the challenges associated with monitoring concentration changes of cytokines over
time.

2

1.2 Microdialysis Sampling
Microdialysis sampling is a minimally-invasive diffusion-based technique commonly used to
sample from many different tissue spaces

21

11, 22

and is starting to be used extensively in humans.

The

efficiency of microdialysis sampling during cytokine or protein collection is commonly represented as
23, 24

either relative recovery (RR) or extraction efficiency (EE).

Relative recovery has been defined by

Bungay et al. as the ratio of the biomolecule concentration of interest collected after microdialysis
24

sampling (Coutlet) and the concentration of this biomolecule far away from the collection point (Csample,∞).
The latter statement can be simplified with the following equation:
Equation 1.1
RR =

Coutlet
Csample, ∞
25

Relative recovery (RR) or extraction efficiency (EE) is defined as:
Equation 1.2
RR = EE = 1 – exp

-1

Qd Rd + Rm + Rq 

In this equation, Qd represents the flow rate; Rd , the mass transport resistance of the quiescent
medium external to the microdialysis probe; Rm , the mass transport resistance of the dialysate; and Rq ,
the mass transport resistance of the membrane. More specific terms are shown on Table 1.1. Equation
1.2 takes into account all the variables associated with influencing the amount of material recovered
during the collection of any biomolecule using a microdialysis probe. To clarify, it is important to define
23,25

and schematically represent each variable of Equation 1.2,

see Figure 1.1,

23

22

and Table 1.1.

The

poor collection or EE performance of microdialysis sampling when used to collect certain biomolecules
such as cytokines is due to several factors: a) mass transport resistances, see Table 1.1, b) biomolecular
diffusion rate, c) the pore size of the microdialysis membrane as well as whether the membrane is
hydrophobic or hydrophilic, and d) their low concentrations that change rapidly.

24

As a result, quantifying

cytokines collected using microdialysis sampling method is challenging.

3

Cytokines are known to bind different biomolecules such as complex sugars (for example
26

heparin),

26

antibodies,

and aptamers

27, 28

which brings the opportunity of creating affinity based methods

to improve the collection of these proteins from tissue spaces during microdialysis sampling. Aptamers
are oligonucleotides with similar properties than antibodies generated using a process called Selective
27, 29

Evolution of Ligands by Exponential enrichment (SELEX).

According to Chris Le et al “aptamers are
28

short nucleic acid sequences that are used as ligands to bind their targets with high affinity”.

Inner cannula

Sample medium (q)

Sample medium (q)
L

Membrane

23

Figure 1.1 Schematic CMA/20 10 mm polyethersulfone microdialysis layout.

4

Table 1.1 List of equations and variables of relative recovery equation, see Equation 1.2
Equations

Rq =

1
2πDq Φq 2r0 L

Definition

Variables

Mass transport resistance of

Φq = Volume fraction for quiescent

the quiescent medium

medium

external to the microdialysis

r0 = Outer radius of membrane

25

probe

L = Effective membrane length
ri = Inner radius of membrane

13ri - rα 
70πLri Dd

Rd =

Mass transport resistance of
25

the dialysate

rα = Inner radius of cannula
Dd = Diffusion coefficient in the
dialysate

r
ln  0 
ri
Rm =
2πLDm Φm

Dd =

6.85 x 10-15

Mass transport resistance of
25

the membrane

occupied by water
η = Dynamic viscosity

Aqueous diffusion

1

η *M3 .RG

Φm = Membrane volume fraction

M = Molecular weight

25,30

coefficient

RG = Radius of gyration
λ=

rs
rp

Ratio of analyte radius to
pore radius

31

rs = Radius of analyte
rp = Radius of pore size

Hm = K(1-2.1044λ + 2.089λ3 - 0.948λ5 )

Diffusion hindrance factor

K = 1 - λ2

Partition coefficient

32

33

Effective membrane diffusion coefficient

Dm = Daq 1 - λ2 (1 - 2.104λ + 2.089λ3 - 0.948λ5 )

using the diffusion hindrance factor

34

Several researchers have created affinity based methods to improve the relative recovery of
5, 24, 35

cytokines using microdialysis sampling technique.

Affinity-based methods could be defined as

methods that take advantage of the binding affinities of two biomolecules or molecules. For instance, Duo
et al. developed a method to improve cytokines relative recovery using affinity agents such as antibodies
26

and heparin attached to polystyrene microspheres.

Their method consists of perfusing polystyrene

5

microspheres of 5.99 µm o.d. with an immobilized affinity agent, for example antibodies, through the
microdialysis probe during cytokine protein collection to increase their mass transport across the
26, 35

membrane pores.

According to Duo, heparin is an affinity agent more suitable for the capture and
36

release of cytokines from functionalized microspheres than antibodies.

-5

-1

Antibodies have slower (10 s )

dissociation rate constant (koff), are less chemically stable, and are more expensive than heparin (koff =
-2

-4

-1 36

10 to 10 s ).

When antibody-immobilized beads are used as affinity agents during microdialysis sampling
followed by direct measurements of dialysates containing the cytokines on the beads (flow cytometry)
only one measurement can be performed if the concentration of the cytokine is too high (>5000 pg/mL).
The problem with the flow Cytometry, immunoassay bead based detection, is that their design (Luminex
or BD technology) only allows the beads or sample to be measured once, so further dilutions of a sample
36

that is saturated or over range are not possible.

However, some research groups have developed

methods or techniques that allow dilutions of samples if needed using microfluidic system. For example,
Ligler and Kim developed a microfluidic system or “microflow cytometer” using bead-based techniques to
37

measure multiple analytes at the same time.

The advantage of their system is that functionalized

microspheres (having the analyte bound to them) can be recovered and measured more than once if
necessary.
Another issue is that

acidic (pH~4) dissociation reagents are required in order to release

cytokines from antibody-immobilized microspheres which interfere with the assay performance and could
36

denature the antibody.

In contrast, mild conditions (30% (v/v) acetonitrile) are used to dissociate
36

cytokines from heparin functionalized microspheres. This makes heparin a more “flexible” affinity agent
than antibodies facilitating measurements, trapping and release of cytokines. However, using heparin as
an affinity agent does not completely solve the quantitation issues when low concentrations of cytokines
are collected. As a consequence, further pre-concentration of cytokines using heparin-microspheres is
desired.

6

1.3 Heparin
36

Heparin, see Figure 1.2,

belongs to the family of glycosaminoglycans (GAGs). Highly sulfated

glycosaminoglycans such as heparin and heparan sulfate are known to have affinity for several cytokines
such as regulated upon activation, normal T-cell expressed and, secreted (RANTES) or C-C motif Ligand
5 (CCL5), monocyte chemotactic protein-1 (MCP-1) or C-C motif Ligand 2 (CCL2), macrophage
38, 39, 40, 41

inflammatory protein-1 (MIP-1), tumor necrosis factor-alpha (TNF-α), and interleukin-8 (IL-8).

Moreover, according to Linhardt and Capila the interactions between heparin and proteins are mainly
39

ionic.

They also pointed out that either carboxyl or sulfo groups on heparin form ion pairs with positively

charged amino acids on proteins. In addition, hydrogen bonding or nonionic interactions between heparin
39

and proteins are also present in some instances.

Finally, heparin is a suitable affinity agent commonly

used in biomedical related areas, because it can be attached to amine or carboxyl functionalized surfaces
or microspheres via reductive amination or end point attachment with well-established chemical
42, 43

procedures.

Uronic acid

Glucosamine

Variable sequence
Major sequence

Heparin
-

Figure 1.2 Major and minor disaccharide repeating units in heparin (X = H or SO3 , Y =
-

36

Ac, SO3 , or H).

7

1.4 Microspheres
Magnetic microspheres are widely used both in vivo and in vitro in many research areas such as,
44

analytical chemistry, biomedical,
47, 48

medicine,

49

molecular biology,

45

chemical and bio-engineering, drug targeting,
nanotechnology,

48, 50

46

microfluidics,

and proteomics. One of the most common

applications of magnetic microspheres is as carriers to deliver specific biomolecules into biological
systems or any other systems such as microfluidics. Also, magnetic microspheres can be used to extract
49, 51,52

or capture biomolecules, viruses or bacteria from different systems.

Another application in which magnetic microspheres have been used is in microfluidics devices.
49

Veyret et al devised magnetic colloids to capture viruses.

They made magnetic colloids from oil in water

magnetic emulsions in which poly (ethyleneimine) and poly (maleic anhydride-co-methyl vinyl ether) were
adsorbed in two separated steps on the emulsion droplets. Veyret and co-workers could achieve a yellow
fever virus capture efficiency of 90% from human serum. They performed several steps to isolate, purify,
and detect the yellow virus from human or phosphate buffer saline using magnetic microspheres. Rittich
53

et al functionalized magnetic microspheres with hydrophilic properties for molecular applications.

In their

research, they developed magnetic nonporous hydrophilic microspheres by polymerizing poly (2hydroxyethyl

methacrylate-co-ethylenedimethacrylate)-(P(HEMA-co-EDMA)),

poly(2-hydroyethyl

methacrylate-co-glycidyl methacrylate)-(P(HEMA-co-GMA)), and poly(glycidyl methacrylate)-(PGMA) with
a stable colloidal solution of magnetite on one step process. Also, they functionalized the magnetic
microspheres with different enzymes such as RNase A, DNase I, proteinase K, and Salmonella
antibodies to isolate Salmonella cells and degrade bacterial RNA, chromosomal, and plasmid DNAs. Choi
54

et al developed a new magnetic bead-based a device for integrated bio-detection systems.

He and his

colleagues devised a filterless bio-separator system to trap functionalized magnetic microbeads on a flat
surface to separate specific biomolecules from a carrier fluid and treat them chemically to release and
detect analytes of interest. However, magnetic microspheres approaches to pre-concentrate cytokines or
proteins have not been reported before. Most of the research work found in the literature is about pre52

concentration of viruses.

One of the novel aspects of this thesis was the used of magnetic microspheres

to pre-concentrate cytokines or proteins.

8

1.5

Microfluidics
Studies and creation of microfluidic sytems is an interdisciplinary research area integrating

scientists and non-scientists from different disciplines such as Mechanical, Electrical, Computer
Engineering, Chemistry,Physics and Biology on the quest for faster, cheaper, and smaller devices able to
solve many different types of problems. One of the principal advantages of this research area is that
commonly used analytical instruments or techniques such as High-performance liquid chromatography
(HPLC), mass spectrometry (MS), and microdialysis sampling can be coupled to microfluidic
55,56,57

systems.

This makes microfluidic sytems a very versatile research area.

58

In contrast, most of the

well-known fluid mechanics laws used for macrosystems cannot be applied to microsystem or
59,60,61

microfluidics in some cases.

That is one of the main drawbacks of this research area. To explain,

most research depends on experimental information to evaluate the flow behavior in microfluidic
60,61,62

systems.

This thesis had several goals. First, immobilization and quantitation of heparin onto either
polymer or magnetic microspheres to capture cytokines and improve RR of cytokines after microdialysis
sampling was pursued. Second, development of an equation to estimate the amount of heparin required
(initial concentration) to be immobilized to beads to bind > 99% of cytokines at equilibrium. The amount of
heparin included in the calculations was related to the amount of heparin-functionalized microspheres to
be able to design a system based on the amount of heparin-functionalized microspheres necessary to
pre-concentrate cytokines. Finally, design, fabricate, and test a microfluidic system to trap and release the
heparin-functionalized microspheres after microdialysis sampling in order to further pre-concentrate
cytokines.

9
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Chapter 2. Immobilization, Testing, and Pre-concentration Approach for Microfluidics Systems
Applications of Heparin Functionalized Microspheres

2.1 Introduction
This chapter describes how heparin was chemically attached to amine functionalized polystyrene
and carboxyl functionalized magnetic microspheres via reductive amination and EDC (N-(3Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) /NHS (N-Hydroxy-succinimide) chemistry,
respectively. Two types of surface chemistry or functionalized microspheres were used due to the
commercial unavailability of amine functionalized magnetic microspheres. Therefore, two immobilization
procedures were used; one for polystyrene microspheres (NH2-functionality) and one for magnetic
microspheres (COOH-functionality). After immobilization the amount of heparin on the microspheres was
measured following hydrolysis using a liquid chromatography with pulsed amperometric detection (LCPAD) system. Following this measurement the heparin-functionalized microspheres were tested for their
binding capacity with cytokines (MCP-1 and TNF-α) by measuring the interactions between them using
two equilibrium methods, see below. In other to prove that heparin functionalized microspheres could be
used to pre-concentrate cytokines and to determine the amount of heparin functionalized microspheres
needed to reach ~ 100% of cytokines bound, a set of equations was derived and calculations were
performed. These calculations were based on reported binding constant values for interactions between
cytokines and heparin.
2.1.1 Immobilization and characterization of heparin
2.1.1.1 Magnetic microspheres
In order to trap and release cytokines from magnetic microspheres several experiments were
conducted. First, heparin was immobilized onto carboxyl functionalized superparamagnetic microspheres
1

of 6.3 µm mean diameter using the immobilization procedure described by Chung, et al. Second, the
amount of heparin immobilized onto the magnetic microspheres was quantified using a LC-PAD method
2

3

similar to a method used by Duo combined with a modified acid hydrolysis method. The method used by
Duo was based on the quantitation of glucosamine present in heparin after acid hydrolysis. The amount
of glucosamine present in heparin after hydrolysis is approximately ~20% and varies depending on the

14

4

acid hydrolysis method used.

Moreover, according to Rohrer et al., glucosamine is the only
5

monosaccharide present in heparin after acid hydrolysis.
2.1.1.2

Polymeric microspheres
Heparin was attached to amine functionalized polystyrene microspheres of 6 microns via
2

reductive amination. The quantitation of heparin immobilized on the polystyrene microspheres was
performed by using the same procedure mentioned in section 2.1.1.1 and more fully described in section
2.2.3.1. The idea of using heparin functionalized polystyrene microspheres was to demonstrate that
cytokines could be pre-concentrated in a bead-based microfluidic system coupled to microdialysis
sampling. In addition, heparin is cheaper than antibodies. However, antibodies are more specific than
heparin. In other words, heparin can bind more than one biomolecule or cytokine. This can have a great
impact during in vivo experiments and would certainly need to be tested as future work.
2.1.2

Testing of heparin functionalized microspheres

2.1.2.1

Polymeric microspheres
To test the heparin-functionalized polystyrene microspheres interactions with cytokines

equilibrium dialysis was used. Equilibrium dialysis is a technique commonly used to evaluate binding
6-8

interactions between biomolecules of different molecular weights (ligand and receptor).

Typically an

equilibrium dialysis system is composed of two chambers and a membrane separating them, see Figure
6,8

2.1.

Cellulose acetate membrane 100 kDa

Chamber 1

Chamber 2

Figure 2.1 Schematic representation of the equilibrium dialysis system used to measure the heparin6

cytokines interaction.
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In principle the idea of conducting equilibrium dialysis experiments is to allow a small ligand
(smaller than membrane pore size) to diffuse across a membrane to interact with a receptor or other
6-8

biomolecule that is retained due to the membrane pore size.

In other words, the ligand diffuses across

the membrane and interacts with the receptor whereas the receptor cannot diffuse across the membrane
to interact with the ligand due to its molecular weight being greater than the molecular weight cutoff of the
membrane. At equilibrium, the concentration of the small ligand (free) will be the same in both
6-8

chambers.

This allows calculation of the amount of ligand bound to the receptor by measuring the free

concentration of the ligand and conducting a mass balance. Even though equilibrium dialysis experiments
are commonly conducted by using biomolecules of different molecular weights, binding interactions
between biomolecules of the same or similar molecular weights can be performed as well under certain
conditions. For instance, the equilibrium dialysis system used for studying the binding interactions
between heparin (~12 kDa) and cytokines (8 to 80 kDa) was composed of two chambers of 25 µL each
6

and a cellulose acetate membrane of 100 kDa molecular cut off (MWCO). In this instance both heparin
and cytokines have similar molecular weights and are smaller than the membrane pore size. However,
since heparin is attached to the 6 µm polystyrene microspheres, this prevents heparin from diffusing
across the membrane. This way only cytokines can diffuse through the membrane pores.
2.1.2.2

Magnetic microspheres
To test the heparin-functionalized magnetic microspheres, ratMCP-1 and ratTNF-α were used.

Heparin-functionalized magnetic microspheres and cytokines were incubated in plastic vials to test their
2

2

binding interactions. The method used to study this interaction was the same used by Duo. His method
consisted of placing equal volumes of a solution of heparin-functionalized microspheres in PBS and
cytokine solution (in the same buffer) in a plastic vial and incubated it for two hours (i.e. MCP-1) at room
2

temperature unless otherwise stated (see experimental section).

2.1.3 Proof of principal pre-concentration approach using heparin functionalized polystyrene
microspheres
To evaluate the limitations of using heparin immobilized on microspheres to trap and release and
pre-concentrate cytokines and to have an estimate of the amount of heparin-immobilized beads needed
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to achieve a particular pre-concentration, several calculations were conducted. These calculations were
compared to the binding values obtained from the equilibrium experiments of section 2.1.2. The following
set of calculations for the heparin-cytokines chemical interactions assuming a 1:1 binding interaction,
9-12

which is commonly used for binding calculations,

and using reported binding constants of heparin-

2

binding cytokines.

2.1.3.1 Calculations set up
H = Heparin; C = Cytokine; HC = Complex (Heparin - Cytokine); [H]f = Concentration of free heparin;
[C]f = Concentration of free cytokine; [H]T = Total concentration of heparin; [C]T = Total concentration of
cytokines; [HC] = Concentration of the complex
Chemical equilibrium
k

on
H + C ↔koff
HC

Equation 2.1 Binding constant
KD =

H f. C
koff
=
kon
[HC]

f

Equation 2.2 [H]T = [H]f + [HC]

Equation 2.3 [H]f = [H]T – [HC]

Equation 2.4 [C]T = [C]f + [HC]

Equation 2.5 [C]f = [C]T – [HC]

Substituting equation 2.3 and 2.5 in equation 2.1
Equation 2.6
KD =
Rearranging equation 2.6

([H]T - [HC]) ([CT ] - [HC])
[HC]

KD [HC] = ([H]T - [HC]) ( [C]T - [HC])

KD [HC] = [H]T [C]T - [C]T [HC] - [H]T [HC] + [HC]

2

2

[C]T[H]T + [HC]KD – [HC] [H]T – [HC] [C]T – [HC] = 0
Common factor [HC]

2

Equation 2.7 [H]T [C]T + [HC] (KD + [H]T + [C]T) – [HC] = 0
2

Equation 2.7 has the form ax + bx + c = 0 and we can apply the quadratic formula,
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x=

- b ± b2 - 4ac
2a

x = [HC]; a = 1; b = - ([H]T + [C]T + KD); c = [H]T[C]T
Equation 2.8

HC =

[HT ] + [CT ] + KD  ±

[HT ] + [CT ]+KD  - 4([HT ] [CT ])
2

2(1)

Equation 2.8 was used to estimate the percentage of cytokine bound to heparin at different initial heparin
concentrations for a specific amount of initial cytokine concentration. The results calculated from this
equation are shown in the results section, Table 2.3. The change on the percentage of cytokine bound to
heparin as a function of the initial heparin concentration was evaluated for a fixed initial cytokine
concentration of 1.0 nM (see Figure 2.7).
2.1.4 Hemacytometer
The microspheres concentration (magnetic or polymeric) used in all the experiments in this thesis
were measured using a hemacytometer. This technique is commonly used to count blood cells in
samples. According to Warren “a hemacytometer is a special type of microscope slide that is divided into
13

squares of a defined area over which a defined volume of cell suspension is distributed”.

To explain,

microspheres in solution are placed in the hemacytometer chambers and counted one by one under a
13

microscope.

Other methods for counting microspheres include ImageJ, a freeware software used to
14

process images. This software processes images coming from a microscope with a video system.
This chapter is going to focus on the immobilization, quantitation, and testing of heparin
immobilized onto polymeric or magnetic microspheres and proof of principle of pre-concentration
approach for microfluidics systems applications.
2.2 Experimental Section
2.2.1 Chemicals
8

Carboxyl functionalized superparamagnetic microspheres (3.45 × 10 beads/mL) of 6.3 µm mean
diameter (COMPEL) were obtained from Bangs Laboratories, Inc. (Fishers, IN). Amine functionalized
18

8

polystyrene microspheres (6.00 µm o.do, stock concentration of 2.10 x 10 particles/ml in water) were
purchased

from

Polysciences,

Inc

(Warrington,

PA).

N-Hydroxy-succinimide

(NHS),

N-(3-

Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), 2- morpholinoethanoesulfonic acid
(MES), albumin, from bovine serum (BSA), heparin sodium salt (from porcine intestinal mucosa), D-(+)Glucosamine hydrochloride were from Sigma-Aldrich (St. Louis, MO). The hemacytometer was purchased
from Hausser Scientific (Horsham, PA). A liquid chromatography instrument (LC) was used (Shimadzu
LC-10AD, Japan). An anion-exchange column, Dionex CarboPac PA1 (250 x 2mm), with a CarboPac
PA1 Guard column (50 x 2 mm) were used (Sunnyvale, CA). The detector was a Decade EC detector
with a gold electrode (Antec Leyden, The Netherlands). Micro-Equilibrium Dialyzer of 25 µL and Cellulose
Acetate

membrane
6

Massachusetts).

MWCO

100

kDa

were

purchased

from

Harvard

Apparatus

(Holliston,

Standards (recombinant proteins) and ELISA kits for rat MCP-1 and rat TNF

respectively were obtained from BD Biosciences (San Diego, CA). All other chemicals used were
analytical grade unless otherwise stated.
2.2.2

Immobilization of heparin onto microspheres

2.2.2.1 Carboxyl functionalized superparamagnetic
Heparin was immobilized on carboxyl functionalized magnetic microspheres of 6.3µm using the
same procedure that Chung, et al., reported for the immobilization of heparin on carboxyl porous
1

poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres. Typically 200 µL of stock solution of carboxyl
8

functionalized superparamagnetic microspheres (3.45 × 10 beads/mL) were washed three times with 200
µL 0.1 M MES buffer (pH 5.5) and reconstituted with the same buffer. After that 47.9 mg of EDC and 28.8
mg of NHS were added to the solution followed by the addition of 30 mg/mL of heparin. This solution was
1

incubated overnight under constant rotation. After the incubation the amount of heparin immobilized was
determined by using an acid hydrolysis method combined with a LC-PAD system, see section 2.2.3.
2.2.2.2

Amine functionalized polystyrene
The protocol for the immobilization of heparin was as follows: 200 µL of stock solution of amine
8

functionalized polystyrene microspheres (2.10 x 10 beads/mL) was taken and washed three times with 1
mL of 0.2 M sodium phosphate buffer, pH 7.0 and then reconstituted in 1.5 mL of the same buffer having

19

30 mg/mL of heparin and 3 mg/mL of NaCNBH3. After that the colloidal solution was incubated on a
microplate shaker at 1000 rpm at room temperature for 2 days. To be able to compare the amount of
heparin immobilized onto the microspheres control microspheres were prepared following the above
procedure without heparin. The solution containing the microspheres was washed three times with 0.2 M
sodium acetate buffer, pH 7.0 to eliminate any non-covalently bound components and reconstituted in 1
mL of the buffer. Then 1 mL of acetic anhydride was added to the colloidal solution and incubated for 1
hour at room temperature to deactivate the unreacted amine groups. Next, the microspheres were
washed with HPLC water, 0.1 M NaOH, and 10 mM phosphate buffered saline (PBS) pH 7.4. The
2

colloidal solution was stored in 10 mM PBS pH 7.4 containing 0.05% sodium azide. Before and after
heparin immobilization, microspheres were counted using a hemocytometer in order to determine if any
microspheres were lost during the immobilization process. To clarify, 10 µL of the microspheres solution
was placed in each chamber, placed under microscope, and counted. The heparin concentration
immobilized to the microspheres was determined by hydrolyzing the microspheres solution and
quantifying it as the amount of glucosamine present after acid hydrolysis. The standards were used
based on the heparin lot used for immobilization to diminish any lot variation as heparin is very
heterogeneous and can vary from lot to lot.
2.2.3

Characterization or quantitation of heparin immobilized

2.2.3.1

Polystyrene and superparamagnetic microspheres
The acid hydrolization process used was a modified version of the method for heparin quantitation
3

found on the Pharmacopeial Forum. A glucosamine standard solution was prepared by taking ~0.2
mg/mL of glucosamine hydrochloride RS in 4.8 M hydrochloric acid. An aliquot of ~625 µL of this standard
solution was transferred to a 2.0 mL graduated plastic vial with attached lid, and heated for 6 h at 100°C
in a sand bath. Then the heated solution place in a micro-vial rack at ambient temperature for one hour
and then was quantitatively transferred to a 2 mL volumetric flask, and diluted with HPLC grade water to
volume. The standard solution of heparin was prepared by transferring a known weight of heparin sodium
(targeted ~1.5 mg) to a 2 mL graduated vial with attached lid, dissolved in 2 mL of 4.8 M hydrochloric
acid, and capped. The standard solution of heparin was heated for 6 hours at 100°C in a sand bath, then
the solution was placed in a micro-vial rack until it reached room temperature, and diluted with HPLC
20

grade water (3 in 50) unless otherwise stated (2 mL volumetric flask). Heparin-functionalized polymeric or
magnetic microspheres were hydrolyzed and the concentrations of glucosamine obtained were compared
to the standard solutions. After hydrolysis the microspheres were centrifuged and the supernatant was
diluted (3:50) in HPLC-grade water. Several calibration curves were generated with the hydrolyzed
standards prepared above. First, the hydrolyzed heparin was used to generate a calibration curve based
on the amount of glucosamine. Second, the standard solution of hydrolyzed glucosamine of different
concentrations was used to generate a calibration curve and compare analyzed amounts to the free
hydrolyzed heparin, see Figure 2.2. The amount of glucosamine in the hydrolysate from the
microspheres, and standard solution of glucosamine were quantified by ion-exchange chromatography
with pulsed amperometric detection (LC-PAD). An anion-exchange column, Dionex CarboPac PA1, with a
CarboPac PA1 Guard column was used. The detector was a Decade EC detector with a gold electrode
in the pulse potentials and time durations of E1 = +0.05 V, t1 = 400 ms; E2 = +0.75 V, t2 = 200 ms; E3 = 2

0.75 V, t3 = 400 ms. The mobile phase used was 95 mM sodium hydroxide with 10 mM sodium acetate,
2

and the injection volume 10 µL. The flow rate for the LC was 0.25 mL/min using an isocratic mode.
2.2.4

Testing of heparin immobilized

2.2.4.1 Polystyrene microspheres
A standard solution of rat MCP-1 (289 ng/mL according to the label) was used to prepare the
standards for the ELISA, and solutions used in equilibrium dialysis experiments. An aliquot of 25 µL of
-7

heparin functionalized polystyrene microspheres (4.48 x10 beads/mL) with a total concentration of 5.22
-7

x 10 M of heparin was placed in one of the equilibrium dialyzer chambers and 25 µL of 0.1 or 1.0 nM
2

(reported MW 26.2 kDa) ratMCP-1 diluted in 10mM phosphate buffer saline (PBS, pH 7.4) containing
6

0.05% BSA were placed on the other chamber (Figure 2.1). Controls were prepared as follows: a) 25 µL
of the same ratMCP-1 solution was placed in one chamber, and 25 µL of the same buffer was placed on
the other chamber, and b) 50 µL of the same ratMCP-1 solution was placed in a plastic vial. Samples and
controls were incubated for two hours at room temperature under constant rotation using a horizontal
rotator to allow equilibrium to occur. The time frame of two hours were chosen based on the binding
2

kinetics data reported by Duo for MCP-1 and heparin functionalized microspheres. The control placed in
the plastic vial was incubated with no rotation. After two hours 5 µL aliquot from each equilibrium dialyzer
21

chamber was taken and diluted in 126 µL of ELISA kit assay diluent. Also, 13 µL aliquot from the plastic
vial was diluted in 327 µL of the assay diluent. Standards solutions of ratMCP-1 for ELISA kit were
prepared according to the BD Biosciences procedure (standards were diluted in assay diluent as well).
Standard solution of
heparin containing 4.8
M HCl (in a 2.0 mL
graduated plastic vial
w/attached lid)

Standard solution of
glucosamine containing
4.8 M HCl (in a 2.0 mL
graduated plastic vial
w/attached lid)

Heparin-functionalized microspheres
and amine or carboxyl functionalized
microspheres solution containing 4.8
M HCl (in a 2.0 mL graduated plastic
vial w/attached lid)

Heated for 6 h at 100°C
in a sand bath system

Placed in a micro-vial rack until reached
room temperature (~ 1 hour)

Standard solutions were diluted
(3:50) with HPLC-grade water

Microspheres were centrifuged and
supernatant was diluted (3:50) in HPLC-grade

10 µL of standard solution of heparin, glucosamine and
supernatant were injected separately into the LC-PAD system
to generate two calibration curves and measure the amount of
glucosamine in the supernatant (this was done in triplicate)
Calibration curve of glucosamine used to calculate the amount
of glucosamine in the standards of heparin

The average of the amount of glucosamine in the standards of
heparin was determined and used to back calculated the
amount of heparin immobilized onto the microspheres

Figure 2.2 Flow chart of the method used to determine the amount of heparin immobilized onto the
microspheres based on the glucosamine content.

A calibration curve of ratMCP-1 standards was used to calculate the concentration of samples and
controls. These experiments were performed in triplicate.
22

2.2.4.2

Magnetic microspheres
2

The method for trapping and releasing cytokines was similar to the method used by Duo. A
8

solution, 100 µL, of heparin-functionalized magnetic microspheres (3.90 × 10 beads/mL) with a total
-7

concentration of 4.98 x 10 M of heparin in 10 mM PBS (pH 7.6) was placed in a plastic vial along with a
100 µL solution of either ratMCP-1 (15 ng/mL) or rat TNF-α (5 ng/mL) in the same buffer at different
concentrations. These concentrations were selected based on the estimated values of the amount of
cytokines bound to heparin, see section 2.1.3 and Table 2.3, and the volume (≥ 50 µL) and concentration
needed to make three measurements using the ELISA kit within the kit’s concentration range (31.3 to
15

2000 pg/mL).

The concentration of ratMCP-1 used was higher compared to rat TNF-α because MCP-1

has a higher affinity to heparin, see Table 2.3. In other words, in order to obtain a free concentration of
MCP-1 within the kit’s concentration range a higher initial concentration was used. The plastic vial
containing both solutions was incubated at room temperature for 2 hrs. After incubation, the supernatant
was removed and the cytokine content in the supernatant was determined using the corresponding rat
MCP-1 or rat TNF-α ELISA kit.
A TecanSPECTRAFluor 96-wells plate reader was used to read the absorbance at 450 nm,
wavelength correction was used to subtract absorbance at 570 nm from absorbance 450 nm according to
the BD Biosciences technical data sheet.
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The concentration of cytokines bound to the heparin-

functionalized magnetic beads was determined by subtracting the initial or free concentration of cytokines
that was placed in the vials before incubation to the free concentration of cytokines after incubation or
centrifugation. In other words, the concentration of cytokines bound to the heparin-functionalized
magnetic microspheres was calculated by difference (initial minus free = bound).
2.2.5

Proof of concept pre-concentration approach using heparin functionalized polystyrene
microspheres

2.2.5.1 Estimations
Equation 2.8 was configured in a Microsoft Office Excel 2007 spreadsheet to facilitate the
calculations. A set of calculations were performed manually or by hand to confirm the spreadsheet set up
was working. The steps followed to estimate the amount of heparin functionalized microspheres require to
achieve ~ hundred percent of cytokines bound to heparin were: a) The concentration of heparin
23

6

immobilized on 6 µm microspheres ([HB]) used was 15.7 x 10 heparin molecules per bead, b) the initial
5

concentration ([B]) value used for “plain” microspheres or without heparin was 7.70 x 10 beads/mL, and
c) the final concentration of heparin immobilized on the microspheres ([HB]) was calculated based on the
following equation:

HB =

2.3

HB B 1000
6.023 x 1023

Results and discussion

2.3.1 Characterization or quantitation of heparin immobilized
The amount of heparin immobilized on either heparin-functionalized polystyrene microspheres or
heparin-functionalized magnetic microspheres was calculated using the appropriate calibration curve, and
the calculated glucosamine content ~35.0% and ~27.0%, respectively. Different heparin lots were used to
make polystyrene and magnetic microspheres. That is why the glucosamine content was different, see
section 2.2.2.2. Glucosamine content was calculated as follows: a) The peak areas of heparin hydrolyzed
standards, were plugged in the equations generated by the calibration curves to determine the
concentration of glucosamine, b) The concentrations of glucosamine from “a” were divided by the
predicted concentrations of the heparin solutions or standards prepared (before acid hydrolysis), c) The
results of “b” were averaged and used as the glucosamine content. In order to determine the amount of
heparin measured (after hydrolysis) indirectly the concentration of glucosamine calculated using the
calibration curve were divided by the glucosamine content. The concentration of heparin on heparinfunctionalized polystyrene and magnetic microspheres after acid hydrolysis measured using LC-PAD, see
Figure 2.3, and calculated as explained before is shown in Table 2.1.

Table 2.1 Amount of heparin on heparin-functionalized polystyrene and magnetic microspheres
measured using LC-PAD after acid hydrolysis
Microspheres type

Microspheres concentration (beads/mL)

Polystyrene
Magnetic

4.48 x 10
8
3.90 x 10

7

Heparin concentration (M)
-7

-7

5.22 x 10 ± 0.32 x 10
-7
-7
4.98 x 10 ± 0.08 x 10
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8

The amount of heparin-functionalized magnetic microspheres used was higher (3.90 x 10 beads/mL)
7

than the amount of heparin-functionalized polystyrene microspheres (4.48 x 10 beads/ mL), but the
heparin concentration on polystyrene and magnetic microspheres were approximately the same, see
Table 2.1. The amounts of microspheres used were different, because each stock of microspheres
(polystyrene and magnetic) came with different concentration. The reason why a 10 fold difference
between the amount of heparin-functionalized magnetic and polystyrene microspheres yield
approximately the same amount of heparin immobilized could be due to the efficiency of the coupling
chemistry used due to the differences in available surface chemistries for the beads.
2.3.2

Testing of heparin immobilized

2.3.2.1 Polystyrene microspheres
The interaction of heparin-functionalized polystyrene microspheres and MCP-1 was used to test
the binding capacity of the heparin beads. The method used was equilibrium dialysis. The experimental
results were compared to the estimated values, see Table 2.2. The difference between experiment and
theory were 4.25% for 0.1 nM and 15.08% for 1.0 nM. Since the reported KD values were used for the
estimations this could explain the difference between experiment and theory.
2.3.2.2

Magnetic microspheres

In order to test the heparin-functionalized magnetic beads a different approach was used. This method
was used to minimize the non-specific binding of cytokines. The microspheres were incubated in a plastic
vial with either MCP-1 or TNF-α as explained in section 2.2.4.2. The percentage of MCP-1 bound was
70.38% and for TNF-α was 11.07%, see Table 2.3. These values were expected because MCP-1 has a
higher reported heparin affinity (KD) than TNF-α, see Table 2.5.
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Glucosamine peaks

Blank

Standard of glucosamine

Standard of heparin

Heparin-functionalized microspheres
0.0 1.0 2.0 3.0 4.0 5.0
Retention time (min)

6.0
n=3

Figure 2.3 Chromatograms of standards of glucosamine, hydrolyzed heparin and heparinfunctionalized microspheres after hydrolysis.

26

Table 2.2 Comparison of estimated and experiment of percentage of rat MCP-1 bound to heparin
functionalized polystyrene microspheres
ratMCP-1
Initial
concentration
of heparin (µM)

Initial concentration
of ratMCP-1 (M)

0.52 ± 0.03

1.00 x 10
-10
1.00 x 10

*Reported binding
constant (KD, nM)

% of cytokine
bound

6.60 ± 0.80

98.75
98.75

-9

Calculated binding
constant (KD, nM)
-9

1.00 x 10
-10
1.00 x 10

100.02
30.40

**83.67
***94.50

2

* , **n = 3, ***n = 2
The estimated and calculated percentages of ratMCP-1 and rat TNF-α bound to heparin immobilized
polystyrene and magnetic microspheres were compared see Table 2.4.The differences between
estimated and calculated percentages for those cytokines were 28.31% and 31.56%, respectively. The
difference between the calculated percentages (using measured values) of ratMCP-1 bound to heparin
immobilized polystyrene and magnetic microspheres (1.0 nM and 0.57 nM respectively) was 13.29%. The
estimated percentages (using estimated and reported values) difference was almost negligible (0.06%).
2.3.3

Proof of principal pre-concentration approach using heparin functionalized polystyrene
microspheres

2.3.3.1 Estimations
Several calculations were performed using Equation 2.8. These estimations were conducted for MCP-1,
TNF-α, IL-6, INF-γ, and IL-10 using reported KD values measured using different techniques and
conditions, see Table 2.5. The initial concentration of cytokines used was 1.0 nM and the initial
-10

concentration of heparin was varied from 3.68 x 10
2

-2

M to 3.68 x 10 M. The reason why this range of
-9

concentration was used was that Duo conducted similar calculations using 3.68 x 10 M. However, he
did not show how the calculations were conducted. After conducting my calculations I decided to use his
calculations as a reference and to be able to compare our results I used the same initial concentration
that he used. I obtained similar as Duo.
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Table 2.3 ratMCP-1 and ratTNF-α controls concentration in low binding plastic vials, in equilibrium
dialysis chambers, concentration of free cytokines, and percentages of cytokines bound to heparinfunctionalized magnetic microspheres or heparin after incubation at room temperature for 2 hours.

Control in chambers

ratMCP-1
Sample

% Bound

(ng/mL)

(ng/mL)

(Exp.)

% Bound
(Est.)

13.58 ± 0.36

70.38 ± 1.71

98.69

Control in chambers

4.02 ± 0.23
ratTNF-α
Sample

(ng/mL)

(ng/mL)

% Bound

*5.12

4.56 ± 0.25

*11.07

% Bound
(Est.)
42.63

Table 2.4 Comparison of the estimated and calculated percentages of ratMCP-1 bound to heparin
immobilized polystyrene and magnetic microspheres

Initial
concentration
of heparin (µM)
0.52 ± 0.03

Heparin-polystyrene beads
Initial
*Reported binding
concentration of
constant (KD, nM)
ratMCP-1 (M)
-9
1.00 x 10
6.60 ± 0.80
-10
1.00 x 10

-9

1.00 x 10
-10
1.00 x 10
Initial
concentration
of heparin (µM
0.49 ± 0.01

Calculated binding
constant (KD, nM)
100.02
30.40

Heparin-magnetic beads
Initial
*Reported binding
concentration of
constant (KD, nM)
ratMCP-1 (M)
-9
0.57 x 10
6.60 ± 0.80
Calculated binding
constant (KD, nM)
208.75

% of cytokine
bound
98.75
98.75

**83.67
***94.50
% of cytokine
bound
98.69
% of cytokine
bound
70.38 ± 1.71

2

* , **n = 3, ***n = 2
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After that I conducted a set of calculations as shown on Table 2.5. It was theoretically found (based on
the calculations) that if an initial concentration of cytokine lower than 1.0 nM and any initial concentration
of heparin is used the calculate percentage of cytokine bound to heparin is negligible or constant (data
not shown). In other words, below concentrations of 1.0 nM the estimated % of cytokines bound to
heparin for any initial concentration of heparin remains almost constant. This is a very important finding
for the study of the interactions between heparin and cytokines of cytokine concentrations lower than 1.0
nM.
Several binding curves were generated to ensure that the estimations and derived equation were
in agreement with the fact that for this type of calculations the KD of a biomolecule correspond to the
16

inflection point of its binding curve.

In Figure 2.5 can be seen how each cytokine KD value correspond to

its binding curve inflection point. The amount of heparin required to achieve ~ 100% of cytokines bound
for a fixed initial concentration of cytokines (1.0 nM) was related to the amount of heparin-functionalized
microspheres. This was done to estimate the size of the microfluidic trapping area needed to preconcentrate the cytokines assuming the heparin content to the microspheres and the total microspheres
per mL are known. In Table 2.6 the amount of beads highlighted in red represent the amount of heparinfunctionalized microspheres necessary to obtain ~ 100% of cytokines bound. For MCP-1 and TNF-α, the
9

amount of heparin-functionalized required is higher (7.70 x 10 beads/mL) compared to IL-6, INF-γ, and
8

IL-10 (7.70 x 10 beads/mL). These estimations helped with the microfluidic system design, see Chapter
3.
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Table 2.5 Estimated values of the percentage of cytokines bound to heparin at different [H]f values
KD (M)
Initial
concentration
of Heparin (M)

17

6.70e-07

18

2.00e-07

17

7.47e-08

19

5.40e-08

2

6.60e-09

TNF-α

IL-6

INF-γ

IL-10

MCP-1

3.68e-10

0.05

0.18

0.48

0.66

4.65

3.68e-09

2

0.55

1.8

4.64

6.28

33.63

3.68e-08

5.20

15.49

32.81

40.26

84.49

3.68e-07

35.43

64.75

83.09

87.18

98.23

3.68e-06

84.59

94.84

98.01

98.55

99.82

3.68e-05

98.21

99.46

99.80

99.85

99.98

3.68e-04

99.82

99.95

99.98

99.99

100.00

3.68e-03

99.98

99.99

100.00

100.00

100.00

3.68e-02

100.00

100.00

100.00

100.00

100.00

% of
Cytokine
bound

Note: Numbers in red indicate the initial concentration of heparin required to achieve ~100% of cytokines
bound.
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Figure 2.5 Relationship between percentages of cytokines bound and initial or free heparin at different
concentrations
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Table 2.6 Estimated amount of heparin, [HB], immobilized on amine functionalized microspheres of 6
6

2

microns, [B], based on a reported value of 15.7 x 10 heparin molecules per bead, [HB], at different
initial concentrations of heparin [H]f.

Note: Numbers in read mean the minimum amount of heparin-functionalized beads required to achieve ~
100% of cytokines bound related to Table 2.5.*
2.4 Conclusion
Heparin was chemically immobilized on two different types of microspheres (amine functionalized
polymeric and carboxyl functionalized magnetic). Heparin immobilized to each bead set was quantified
using acid hydrolysis and LC-PAD. The binding affinity of cytokines with heparin-immobilized polymeric
and magnetic microspheres was quantified using equilibrium dialysis and “plastic vial mixing” and
incubation methods. The purpose of these studies was to relate the amount of heparin immobilized onto
the microspheres to the microspheres concentration. In other words, I wanted to determine how many
microspheres were required to obtain an “x” concentration of heparin to further capture an expected “y”
concentration of cytokines. It was estimated theoretically based on experimental data how many
microspheres with a known heparin content were necessary to achieve one hundred percent binding of
cytokines. These estimations and experiments served as a fundamental base for the pre-concentration of
cytokines. For the heparin immobilized polymeric microspheres after equilibrium dialysis (ratMCP-1) the
difference between estimated and experimental values were 4.25% for 0.1 nM and 15.08% for 1.0 nM.
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For heparin immobilized magnetic microspheres after “plastic vial mixing” and incubation (ratMCP-1 and
ratTNF-α) the difference on the percentages were 28.31% and 31.56% respectively. The difference
between the experimental values of the percentages bound between heparin immobilized polymeric and
magnetic microspheres for ratMCP-1 was 13.29%. However, the difference between the estimated values
was almost negligible (0.06%). These differences could be due to the fact that the cytokine KD values
used were obtained from the literature in which each value were obtain under different conditions as
compared to the experiments performed in this thesis. Nevertheless, the difference was lower than
expected. Finally, this work showed that cytokines could be pre-concentrated into a trap and release
microfluidic systems using microspheres with chemical affinity for cytokines.
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Chapter 3. Design, fabrication, and testing of pre-concentrator microfluidic system

3.1 Introduction
In this chapter a simple microfluidic system was created to test the usefulness of heparinimmobilized magnetic microspheres for the pre-concentration of cytokines after microdialysis sampling.
The microfluidic system created is the first system that have been developed using a circular trapping
area to pre-concentrate cytokines. The designed microfluidic system used pressure differences as the
driven force for the fluid. That played an important role on choosing the channels and overall dimensions
of the device in order to facilate fluid flow in the system and to understand the limititaions of the system in
term of flow rate. I was able to use relative high flow rate (10.0 µL per minute) without any leakage for a
system (PDMS-glass) held together by weake forces or Van der Waals forces. Nevertheless, one of the
issues with this new system is that circular-based systems have not been previously described in the
literature. In other words lack of a well-understood and comprehensive fluid mechanics theories for
microfluidics makes the design and characterization of such systems a challenge.
3.1.1 Theory and estimations
Several assumptions were made to be able to estimate the pressure drop of the developed
microfluidic system based on the hydraulic resistance of connected straight channels, the Hagen1

Poiseuille law, and Kirchhoff’s laws or equivalent circuit theory, see Figure 3.1. For pressure driven fluids
microfluidic systems it is common to use the equivalent circuit theory to predict the pressure drop and
analyse or modify designs using well understood electrical circuit theory.

1-5

The aim of this chapter was to

explain how the microfluidic system was developed and tested.
3.2 Design and fabrication
The proposed microfluidic system consisted of several parts: a) A fluidic part having two straight
channels of 0.1 mm (inlet) and 0.2 mm (outlet) having a circular trapping area of 3.6 mm (internal
diameter) between them, see Figure 3.2. The height (0.1 mm) was the same for each channel and
trapping area. The circular trapping area had a volume of ~1 µL equivalent to an estimated amount of ~9
6

x 10 magnetic microspheres of 6 µm in diameter. It was made of polydimethylsiloxane (PDMS), flexible
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6

polymer commonly used for microfluidic fabrication, and b) planar micro-electromagnetic trapping
system. The latter is part of the future work.

Q1

a)

c)
P0

P0 + ∆P1

∆P1 = R1 Q1

Flow direction

Q2
P0 + ∆P2

P0 + ∆P

Q

P0

P0
∆P2 = R2 Q2

b)

R = R1 + R2 + R3

Q3

P0 + ∆P3

∆P = (R1 + R2 + R3) Q

P0 ≡

∆P3 = R3 Q3
Figure 3.1

Equivalent circuit approach of three straight channels in series used to estimate the

pressure drop in the designed microfluidic system, see 3.5.2. a) Inlet and outlet channels, b) circular
trapping area showing the assumption that the cross sectional area of the”circle” was equal to the
cross sectional area of a ”square”, c) the microfludic system. This figure was redrawn and adapted
from reference 1.
Several steps were followed for the fabrication of the microfluidic system. First of all, a 2D sketch
was drawn on AutoCAD 2011 provided by the University of Arkansas’ computer lab, see Figure 3.2. The
dimensions chosen for the design were based on the microfabrication capabilities of the University of
Arkansas’ High Density Electronics Center (HiDEC), and cost. The inlet and outlet microchannels
dimensions were designed to minimize backpressure and to reduce leakage. The idea was to design and
fabricate a system as straightforward, inexpensive, and fast as possible. Finally, the circular trapping area
was designed to have a volume of 1 µL that was related to the minimum amount of heparin-functionalized
magnetic microspheres estimated to reach ~100 % of cytokines bound as explained in Chapter 2.
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20.7 mm
Outlet

Ø 3.6 mm

0.2 mm

0.1 mm

Inlet

20.7 mm

Trapping area

Figure 3.2 2D sketch of the photomask used to fabricate the microfluidic sytem (fluidic part).

The fabrication procedure used to build this system was a standard photolithography or soft
lithography method (see below). After fabricating the system a glass-slide was used to cover the
channels. This system was tested by recording the liquid filling and magnetic microspheres colloidal
solution behavior inside the trapping area.
3.3 Materials and Methods
Carboxyl functionalized magnetic microspheres of 6.0 µm (COMPEL) were obtained from Bangs
Laboratories, Inc. (Fishers, IN). Sylgard 184 silicone elastomer kit base or silicone (Dimethyl siloxane,
dimethylvinyl-terminated major component) and curing agent or silicone resin solution (Dimethyl,
methylhydrogen siloxane major component) was used (Down Corning, Midland, MI. Epoxy based
photoresist or SU-8 was purchased from MicroChem (Newton, MA). Light microscope was purchased
from Leica Microsystems, Inc. (Buffalo Grove, IL). The syringe pump was purchased from BASi (West
Lafayette, IN). A digital camera ViviCam 7388s from Vivitar (New York, NY) was used. Fluorinated
ethylene propylene (FEP) tubing (0.12 mm inner diameter) and tubing adaptors were purchased from
CMA Microdialysis, Inc. (North Chelmsford, MA).
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The microfluidic device in PDMS was fabricated using standard photolithography, see Figure 3.3.
SU-8 was spin coated on a 4” silicon wafer to create a master mold. PDMS was prepared by mixing the
base and curing agent at a 10:1 (w/w) ratio according to the DOW CORNING’s product information
7

sheet. The mixture was degassed using an in-house made vacuum system, see Figure 3.4, and poured
onto the SU-8 master mold. After that the SU-8 master mold was cured in a 75 ºC oven for 1 hour. The
PDMS replica mold was cutted out using a razor blade, removed from the SU-8 master mold, and cleaned
using isopropyl alcohol. After that the device was placed on a standard, previously cleaned using
isopropyl alcohol, microscope glass slide to cover the channels. The interaction between the PDMS and
6

the glass slide form a weak or reversible bond due to the Van der Waals forces. According to McDonald,
et al., this type of bond between PDMS and glass can withstand up to 5 psi, and the amount of residue
6

left after the PDMS is peeled off is significantly low making the fabrication process easier. The inlet and
outlet of the device were made using a round punch having a nominal cutting edge diameter of 0.71 mm
from Technical Innovations, Inc. (Angleton, TX). Finally, the inlet and outlet tubing were placed in the
holes previously made by slightly pushing them in without using any fittings, see Figure 3.5.
3.4 Testing
3.4.1

Liquid filling
In order to test whether or not the system had any leakage and to observe the liquid filling

behavior inside the circular trapping area, HLPC-grade water and 10 mM phosphate buffered saline
(PBS), pH 7.6 were perfused at 1.0 µL/min flow rate in two different set of experiments. During each
individual experiment a video was recorded at 1.0 µL/min flow rate starting at the “entrance” of the circular
trapping area. The video was recorded using an in-house made micro-video recording system composed
of a digital camera attached to a light microscope, see Figure 3.6. Two sets of snapshots were taken after
the experiments were performed, see Figure 3.7, and 3.8.
3.4.2

Microspheres behavior inside circular trapping
8

Magnetic microspheres were taken from a stock solution (3.45 x 10 beads/mL) and washed three times
with 100 µL of 10 mM phosphate buffered saline (PBS), pH 7.6. The microspheres were perfused into the
microfluidic system using a BASi syringe pump. A video of the magnetic microspheres behavior was
39

recorded at different flow rates (1.0, 2.0, 5.0 and 10.0 µL/min) using the micro-video recording system
made in our lab. Several snapshots from the video were taken as illustrated on Figure 3.9.

Spincoat silicon wafer with 5 mL SU-8
photoresist at 1200 rpm for 40 s
SU-8

4” Silicon wafer

Polymerized SU-8

- Prebake 5 min on a hotplate
- Place a negative film glossy side up

-Expose the wafer to the UV lamp
-Postbake 5 min on hotplate
-Develop the wafer in propylene glycol

-To mix base:curing agent (10:1 w/w)
-Build up some PDMS used around
the structure to create a thicker chip
Open microfluidic system
(fluidic part)

Figure 3.3 Simplified microfabrication process of the microfluidic system (fluidic part)
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Figure 3.4 In-house made vacuum system

Figure 3.5 fabricated PDMS microfluidic system with inlet and outlet tubings connected

41

Figure 3.6 In-house made micro-video recording system

“Tail”

Figure 3.7 Snapshots of the liquid filling experiment for HPLC water pumped at 1.0 µL/min. The red arrow
indicates the direction of the flow.
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“Tail”

Figure 3.8 Snapshots of the liquid filling experiment for 10 mM PBS pH 7.6 pumped at 1.0 µL/min. The
red arrow indicates the direction of the flow.

3.4.3

Online and offline collection of microspheres

To evaluate how coupling the microfluidic device to a BASi syringe system (rotator, syringe, and syringe
pump) affected the concentration of amine functionalized polystyrene beads overtime at a fixed flow rate
two set of experiments were conducted. An aliquot of 1.5 µL was taken from amine functionalized
8

polystyrene microspheres of 6.0 µm from stock solution (6.57 x 10 beads/mL) and diluted in 998.5 µL of
6

10 mM PBS having 0.1% polysorbate 20 (Tween 20). The solution (~1.25 x 10 beads/mL) was split in
two 1.0 mL solutions to be used in two different experiments. The amount of beads in these solutions was
measured before and after collection using a hemocytometer. The set up for the experiments was as
follows: First, BASi syringe was filled up with one of the 1.0 mL of amine functionalized polystyrene beads
solution previously made for each experiment. After that the syringe was placed on a rotator to constantly
shake the syringe and keep the amine functionalized polystyrene beads in suspension. A pumping flow
rate of 5.0 µL/min was used for both experiments. Plastic tubing was attached to the syringe tip using a
plastic adaptor for offline sampling or amine functionalized polystyrene beads collection.
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Gap ~0.31 mm

Gap ~0.16mm

Figure 3.9 Snapshots taken from the video that was recorded during the perfusion of magnetic
microspheres into the microfluidic system at different flow rates. The red arrow indicates the direction of
the flow. A) Magnetic microspheres moving away from circular trapping area walls at 10.0 µL/min flow
rate, B) magnetic microspheres moving toward circular trapping area walls at 5.0 µL/min flow rate, C)
magnetic microspheres starting to spread evenly over the circular trapping area at 2 µL/min, and D)
magnetic microspheres spreading evenly over the circular trapping area at 1.0 µL/min flow rate.

For online collection the syringe was coupled to the microfluidic device inlet and amine functionalized
polystyrene beads were collected from the device outlet, see Figure 3.10. Amine functionalized
polystyrene beads were collected in plastic vials every 15 min for 60 min from either the plastic tubing
attached to the syringe tip or microfluidic device outlet. The concentration of amine functionalized
polystyrene beads for each experiment was measured using a hemocytometer.
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Figure 3.10 Experimental set up for the online and offline collection of amine functionalized polystyrene
microspheres of 6.0 µm.

3.5 Results and discussion
3.5.1 Background of the design chosen
The possibility of using polymeric microspheres in the designed microfluidic system was studied.
However, physical traps and hydrodynamic forces were necessary in order to trap and release polymeric
microbeads from a trapping area after chemical analysis. For instance, one of the early ideas was to have
a three channels microfluidic system with a trapping area, see Figure 3.11. The system was composed of
one channel for the injection of the microspheres or inlet dialysate that would be coupled to the
microdialysis outlet, another channel for injection of the dissociation buffer, and the outlet channel. To
explain, the channel used for the injection of dissociation buffer, and the outlet channel would have widths
smaller than 6 µm or any beads size chosen to trap the beads in the trapping area. The idea was to flush
the microspheres out through the inlet (dialysate) channel by injecting a solution in both inlet channel
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(dissociation buffer), and outlet at the same time. The drawbacks of this idea were the following: a)
Channels with widths smaller than 6 µm are very expensive to fabricate (photomask), b) PDMS could
collapse in such a narrow channel, c) Solution of microspheres and buffer must be injected at the same
time (inlet dialysate and inlet dissociation buffer), d) dissociation buffer must be injected in both inlet
channels as well to avoid bead loss, and e) automation was based on hydrodynamic flow control. It is
8

good to point out that after reading Andersson et al article, and evaluating the feasibility of using
polymeric microspheres for the development of a trap and release microfluidic system using physical
barriers magnetic microspheres were chosen. As stated on their article they used standard
8

photolithography, bulk micromachining, deep reactive ion etching, and anodic bonding. Compared to the
two procedures used to make the microfluidic system (fluidic part) using magnetic microspheres on this
thesis their system is more complex and difficult for this initial application. Even if the planar
electromagnetic trapping system was added into the procedures, it would be easier to fabricate than the
Andersson et al system. Also, using an electromagnetic system greatly facilitates the automation process.
Furthermore, none of the previously mentioned research papers used a circular trapping area for their
microfluidic systems. The advantages and disadvantages of using a circular trapping area for microfluidic
applications can be seen on Table 3.1. Pant and his colleagues presented a poster called “System level
9

Simulation of Liquid Filling in Microfluidic Chips”. They used three different abrupt structures, sharp9

rectangle, hexagon, and rounded-rectangle and studied the liquid filling behavior. According to Pant, et
9,10

al., sharp-rectangle abrupt structures or trapping areas tend to trap air bubbles at the corner.

In

contrast, they found that hexagon, and rounded-rectangle abrupt structures did not trap air bubbles.
Compared to sharp-rectangle trapping areas circular trapping areas do not trap air bubbles shown by this
work.
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Outlet
Syringe

Trapping area
Microfluidic device

Microspheres

Front view of the device

Inlet dialysate
Width < microsphere diameter
Inlet dissociation buffer

*

*
Trapping area

Outlet

Top view of the device

Figure 3.11 Earlier proposed microfluidic system with physical traps

47

Table 3.1 Advantages and disadvantages of the circular microfluidic system developed
Advantages
Circular design avoid trapping air (sharp-rectangle
chamber)

9

Easy to fabricate and improve if needed

Disadvantages
Cannot withstand flow rates higher than
10.0 µL/min without leakage
Only one injection port
Channel walls have to be coated to avoid

Cheap and disposable
any non-specific absorption
Bonds between PDMS and glass could
Could be integrated to well-known magnetic trapping
be broken when inserting the inlet or
systems
outlet tubing if care is not taken
Easy to automate or control via software

Not a well understood system

Biocompatible and autoclavable if needed
Useful to study flow behavior in circular chambers
Do not need thermal or oxygen plasma bonding
Does not require complex fittings

3.5.2

Pressure drop estimations
Channels and total pressure drop (∆P) for the microfluidic system was calculated based on the

Hagen-Poiseuille law, see Equation 3.1, for straight channels in series and analogy with the Ohm’s, see
Equation 3.2, and Kirchhoff’s laws for circuit in series, see Figure 3.1, and Table 3.2. The following
assumptions and constants were used: a) Water was flowing in the channels, b) Incompressible flow, c)
trapping area cross sectional area was square, d) volumetric flow rate is constant, e) density of water =
3

1000 Kg/m , f) viscosity of water = 1 mPa.s, g) length of channel 1 and 3 = 20.7 mm, h) length of channel
2 = 3.6 mm, i) height of channels 1,2, and 3 = 100 microns, j) width of channel 1 = 100 microns, channel 2
= 3.6 mm, and channel 3 = 200 microns, and k) Q = 1.0 µL/min. Using equations 3.3, 3.5, 3.7, and 3.8
the total pressure drop was estimated, see Table 3.3. The Reynolds number for each channel was
estimated using equations 3.4, 3.5, and 3.6, see Table 3.3. It was found that the total pressure drop is
directly proportional to the flow rate (data not shown). For instance, the estimated total pressure drop for
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0.5 µL/min was 71.13 Pa, and 1425.99 Pa for 10.0 µL/min. It is good to mention that if the cross section
area of the trapping area (circular) were used on the pressure drop calculations the pressure would be
slightly higher. Two sets of liquid filling experiments were conducted using HPLC water and 10 mM PBS
pH 7.6 at a pumping flow rate of 1.0 µL. The snapshots of each set of experiments are shown on Figure
3.7 and 3.8. PDMS is hydrophobic, so it tends to reduce the fluid flow of water.
Table 3.2 List of equations and variables used for the estimations
∆p = Rhyd Q

Equation 3.1

Hagen-Poiseuille law

Equation 3.2

Ohm’s law
Hydraulic resistance for a
straight channel with
rectangle cross section

Equation 3.3

*Rhyd =

∆V = R I
12 η L

Reynolds number

Equation 3.5

Mean velocity

Equation 3.6

Hydraulic diameter of
rectangular tubes

Equation 3.7

Conservation of flow rate

Equation 3.8

Simple additive law

Equation 3.9

Total pressure drop

Variables

Rhyd = Hydraulic resistance
Q = Volumetric flow rate
η = Dynamic viscosity
L = Length along the
channel axis
h = Height of the channel
w = Width of the channel
A = Area of the channel

*Reference

h 3
1 - 0.63   h w
w

Re =

Equation 3.4

1

1

ρV0 Dh
η

Q
A
2hw
Dh =
h+w

**Reference

11

V0 =

**

***Q = Q1 + Q2 + Q3
*Rhyd = Rhyd1 + Rhyd2 + Rhyd3

*

*∆PT = Rhyd1 + Rhyd2 + Rhyd3  Q
∆V = Potential drop
R = Electrical resistance
I = Electrical current
V0 = Mean velocity
ρ = Density
L0 = Length
***Subscripts refer to: Inlet = 1, Trapping area = 2,
and Outlet = 3, see Figure 3.1

Table 3.3 Results of the estimations for the microfluidic channels
Channel #
1
2
3

Re
0.17
0.01
0.11

-3

Rhyd (Pa.s.m ) x 10
671.35
1.22
181.31

10

∆P (Pa)
112.2
0.20
30.28

∆PT (Pa)
142.60
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Figure 3.7C to E show how the PDMS walls surface limit the fluid flow of water molecules due to the
PDMS inability to form hydrogen bonds with water. To clarify, the flow path of the pumped HPLC water
formed a “tail” that was diminishing as soon as it reached the outlet of the circular trapping area, see
Figure 3.7. The hydrodynamic force generated by pumping HPLC water at 1.0 µL/min is high enough to
break the resistance to fluid flow presented by PDMS (no data shown). In comparison, pumped PBS did
show a slightly “tail” or lesser opposition to fluid flow by PDMS, see Figure 8. This could be explained due
to the fact that typically PBS is composed of four inorganic salts (potassium chloride, potassium
phosphate monobasic, sodium chloride, and sodium phosphate dibasic). This reduces the “repelling”
effect that PDMS has for water molecules. In other words, the interaction between PDMS and PBS is
higher than PDMS and water, because water molecules prefer the salt over the hydrophobic PDMS.
The video taken, see non-print materials, demonstrated that magnetic microspheres tend to focus on the
middle of the circular trapping area at high flow rates (10.0 and 5.0 µL/min), see Figure 3.9–A and 3.9-B.
On the other hand at lower flow rates (2.0 and 1.0 µL/min) magnetic microspheres tend to spread almost
evenly over the circular area, see Figure 3.9-C and 3.9-D. The distance or gap between the walls (middle)
of the trapping area and the stream of magnetic microspheres form next to it is inversely proportional to
the flow rate, see Figure 3.9. Based on the diameter of the trapping area I was able to measure those
gaps. For flow rates of 10.0 and 5.0 µL/min the gap remains approximately constant (~0.31mm). In
contrast, when flow rates of 2.0 and 1.0 µL/min were used the same behavior was observed, but the gap
was ~0.16mm.
These results helped to have a better understanding of how to control the magnetic microspheres
behavior in the trapping area using hydrodynamic force and to determine how long it would take to have
an evenly distributed magnetic microspheres layer. Similar behavior has been studied by several
12,13

researchers for different applications such as beads separation ,

14

and flow behavior.

However, as

mentioned before those studies used square channels. This kind of behavior has not been presented by
any research group as far as the author knows.
In order to evaluate the variation of amine functionalized polystyrene microspheres concentration
after coupling the microfluidic device to a BASi syringe system two set of experiments were performed.
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The initial concentration of amine functionalized polystyrene beads counted before filling up the syringe
6

for the offline collection was 1.25 x 10 beads/mL. For the online collection the concentration was 1.26 x
6

10 beads/mL. The total averages of the relative recovery of amine functionalized polystyrene beads
collected were 66.60 and 66.90% for the offline and online experiments, see Figure 3.12. This indicated
that there were not significant differences between the offline and online collection. To explain, coupling
the microfluidic device to the BASi syringe system did not have any influence on the concentration of
amine functionalized polystyrene beads. These experiments demonstrated that a uniform flow rate can be
achieved when coupling the microfluidic system to a syringe system. Finally, it is very important to
understand how magnetic microspheres behave in circular channels for the development of any trap and
release systems for pre-concentration of biomolecules or other applications.

Figure 3.11 Comparison of the relative recoveries of online and offline collection of 6.0 µm
amine functionalized polystyrene microspheres at 5.0 µL/min flow rate.
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4

Chapter 4. Conclusions and Future work

Cytokines play an important role in the immune response network generated during implants or
prostheses, biosensors, and several disease states. The efficient collection and quantitation of cytokines
during an immune response is crucial. This will allow the monitoring of cytokines concentration changes
over time during any immune response. In other words, better understanding of the role that each
cytokine has during an immunological response. However, this is a very difficult task due to the amount
the variables involves in any biological system. Biological systems are very complex making the study of
cytokines and collection of cytokines challenging. In order to study cytokines in their “native” environment
during a specific state it is important to develop analytical tools that could facilitate the task. It is common
practice, due to its simplicity, the collection and quantitation of cytokines from tissues and blood samples.
The problem is that the concentration of cytokines measured from tissues or blood sample does not
represent the “real” concentration of cytokines. It is more like an indirect measurement of the total
concentration present within their biological environment. In their “native” biological environment the
cytokine concentration is not constant due to their highly biological activity. If an ideal device or system is
to be developed to collect and quantify cytokines it would have to have the following characteristics: a)
Minimally invasive constant collection without disrupting their biological environment, b) constant
measurement or quantitation of different cytokines (multiplexing) overtime with a lower limit of detection of
picomolar and a upper of micromolar, c) easily to use, d) portable, and, e) low cost of fabrication. In reality
some of these characteristic can be found on known systems. For example, microdialysis is commonly
used to sample from tissue spaces. Microdialysis a diffusion based sample technique is limited to the
diffusion properties of the cytokines in their biological environment and across the microdialysis
membrane, the composition of the membrane (hydrophilic or hydrophobic), and the speed of the foreign
body response caused by its “implantation” to mention a few. Research groups such as Dr. Stenken’s
group have been working on improving the collection time of cytokines when sampling with microdialysis
and the recovery of cytokines. The bead-based method developed by her group increased the relative
recovery of cytokines using heparin immobilized microspheres by two-fold in vivo and two to five fold in
1

vitro.
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Quantitation of cytokines is commonly done by using ELISA. ELISA is a great tool to measure low
concentration of cytokines (pg/mL range). However, ELISA is very labor extensive, expensive, time
consuming (~19 hours), requires at least 100 µL of sample (longer collection time) and it is not robust.
These facts add another problem to be solved in order to quantify cytokines efficiently.
Microfluidics is one of the fastest new research areas. This research area work on finding
answers or developing tools to solve complex problems. It is of common knowledge that complex
problems required sometimes more than one research area. For example, cytokines collection and
quantitation requires people with knowledge in Biology, Analytical Chemistry, Engineering (fluid
dynamics, microfabrication and electronics), and Physics (optics, binding interactions). However,
researchers do not need to know the entire “book” if they only need one chapter to solve their problem. In
other words, knowing what is needed of a specific area to solve a complex problem is what microfluidics
brings. Microfluidic systems have several advantages: a) Low cost, b) easy to use, c) low sample volume,
d) easy to fabricate, e) can be coupled to known analytical techniques, and f) well understood systems
can be integrated into it.
The aim of this thesis was to use a bead-based method developed by Dr. Stenken’s group and
integrate it in a microfluidic system coupled to microdialysis sampling to pre-concentrate cytokines. The
bead-based method improves the relative recovery of cytokines and the microfluidic system further preconcentration cytokines to enhance their quantitation.
In Chapter 2 it was shown the ability to reproduce Duo’s work by making heparin immobilized
polystyrene and magnetic microspheres. Also, it was developed a system to determine the amount of
heparin require to achieve ~100% of cytokine bound. This was related to the amount of heparinimmobilized microspheres needed as well based on the amount of heparin immobilized per bead. These
beads were tested using equilibrium dialysis and a simple plastic vial incubation method used by Duo. It
was estimated that the minimum amount of heparin required to achieve ~100% of cytokine bound was
3.68 µM. The comparisons of experimental and estimated values for ratMCP-1 (heparin immobilized
polystyrene beads) were 4.25 and 15.08% difference for 0.1 and 1.0 nM. The percentages differences
between experimental and estimated for ratMCP-1 and ratTNF-α were 28.31 and 31.56%, respectively.
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The differences of the values could be due to the fact that reported binding constant values were used for
the estimations. Part of the future work will be to measure cytokine binding constant to have a better
“control” of the conditions.
A microfluidic system was developed and tested by pumping water and PBS. The hydrophobicity
of PDMS was confirmed by looking at the opposition to fluid flow by the PDMS channels in the trapping
area. Magnetic microspheres flow behavior at different flow rates was tested. The magnetic beads spread
inversely proportional to the flow rate used.
The future work will be integration of a trapping, detection, and automation system to fully collect
and quantify cytokines in real-time.
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